Buradasınız

Anasayfa » Content

LIPID INDICES IN TYPEII DIABETES MELLITUS AND THEIR ASSOCIATION WITH MACRO AND MICRO VASCULAR COMPLICATIONS

LIPID INDICES IN TYPEII DIABETES MELLITUS AND THEIR ASSOCIATION WITH MACRO AND MICRO VASCULAR COMPLICATIONS

Journal Name:

  • International Journal of Medical Research & Health Sciences

Publication Year:

  • 2013

Key Words:

Author Name
Abstract (2. Language): 
Background: Type II Diabetes Mellitus patients can develop complications over a prolonged period of time. The alterations in lipid indices can be associated with these complications. Aims:To identify changes in lipid metabolism in type 2 DM in context with the glycemic status, its relative impact on the macro & micro vascular events, and the effects of insulin therapy on the lipid indices. Methods and Material: 158 Type II diabetics were selected as cases and 30 subjects without any coincidental illness as controls were selected for the study. Total cholesterol, Triglyceride, HDL-C, Cholesterol/ HDL-C ratio and Atherogenic Index (AI) were estimated and the data was statistically analyzed. Results: Atherogenic index and CHOL/HDL-C levels were significantly higher in diabetics than in controls. Both the indices were also found to be lowered in patients on treatment with insulin. The AI in patients with complications was also significantly higher than those without complications; however CHOL/HDL-C was not significantly different. Thus using the best cutoff values AI can be used as a better indicator for complications than using the ratio of CHOL/HDL-C. Conclusion: AI can be used to indicate the presence of increased cardiovascular risk in patients with type II DM, and as a guide for the aggressive therapeutic approach.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-lipid-indices-typeii-diabetes-mellitus-and-their-association-macro-and-micro-vascular-complications.pdf
  • 1
87-92
  • Turkish

REFERENCES

References: 

1. Brown. WV. Lipoprotein disorder in diabetes
mellitus. Medical clinics of North America
1994:. 78, 143-61.
2. Jenny EK et al. Do glucose and lipids exert
independent effects on atherosclerotic lesion
Initiation or progression to advanced plaques?
Circ. Res. 2007;100:769-81
3. Meng HT et al. Pioglitazone reduces
atherogenic index of plasma in patients with
type 2 diabetes. Clin Chem. 2004; 50:7;1184-
88
4. Michael HD. Global risk management in
patients with type 2 diabetes mellitus. Am J
Cardiol 2007; 99:41–50.
5. Sandra JL. Prevention and treatment of
atherosclerosis: A practitioner’s guide for
2008 The American Journal of Medicine.
2009; 122:38-50
6. Allan et al, enzymatic determinations of total
serum cholesterol. Clin Chem. 1974; 20: 470-
75.
7. Friedwald, Levy WT. Estimation of
concentration of LDL-c in plasma without the
use of preparative ultracentrifuge. Clin Chem.
1972; 18; 499-02.
8. Steven M Haffner etal. Mortality from
coronary heart disease in subjects with type 2
Diabetes and in nondiabetic subjects with and
without prior Myocardial infarction. N Engl J
Med 1998;339:229-34.
9. Standards of medical care in diabetes; diabetes
care: 2012; 35,11-S49.
10. David Snipelisky, Paul Ziajka. Diabetes and
hyperlipidemia: a direct quantitative analysis.
World Journal of Cardiovascular Diseases,
2012; 2: 20-25.
11. Lucia Rohrer. High density lipoproteins in the
intersection of diabetes mellitus, Inflammation
and cardiovascular disease. Current Opin
Lipidol.2004; 15:269–27
12. Maxime N. Insulin-Mediated Down-
Regulation of Apolipoprotein A5 Gene
Expression through the Phosphatidylinositol
3-Kinase Pathway: Role of Upstream
Stimulatory Factor. Mol Cell Biol. 2005
February; 25 (4): 1537–48.
13. Auni Juutilainen etal. Type 2 Diabetes as a
Coronary Heart Disease Equivalent: An 18-
year prospective population-based study in
Finnish subjects. Diabetes Care December
2005;28(12): 2901-07.
91
Imran et al., Int J Med J Res Health Sci. 2013;2(1):87-92
14. Diane M Erdman etal. The Impact of
Outpatient Diabetes Management on Serum
Lipids in Urban African-Americans With
Type 2 Diabetes. Diabetes Care January 2002;
25(1): 9-15.
15. Edward JB etal. Does diabetes always confer
coronary heart disease risk equivalent to a
prior myocardial infarction? Implications for
prevention. Diabetes care. 2011;34(3): 782-84.
16. Tangvarasittichai etal. Association of serum
lipoprotein ratios with insulin resistance in
type 2 diabetes mellitus. Indian Council of
Medical Research, May 2010 Volume: 131,
Issue: 5.
17. Byambaa Enkhmaa etal. Postprandial
Lipoproteins and Cardiovascular Disease Risk
in Diabetes Mellitus. Curr Diab Rep. 2010
February; 10(1): 61–69.
18. Richard WN. LDL Cholesterol Lowering in
Type 2 Diabetes: What Is the Optimum
Approach? Clinical Diabetes January
2008;26(1): 8-13.
19. W Todd Cade. Diabetes-Related
Microvascular and Macrovascular Diseases in
the Physical Therapy Setting. Physical
Therapy November. 2008;88(11):1322-35.

Thank you for copying data from http://www.arastirmax.com